Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis
Sancho-Albero, M. (Universidad de Zaragoza) ; Rubio-Ruiz, B. ; Perez-Lopez, A.M. ; Sebastian, V. (Universidad de Zaragoza) ; Martin-Duque, P. ; Arruebo, M. (Universidad de Zaragoza) ; Unciti-Broceta, A. ; Santamaria, J. (Universidad de Zaragoza)
Resumen: P151
The transformational impact of bioorthogonal chemistries has inspired new strategies for the in vivo synthesis of bioactive agents through non-natural means. Among these, Palladium (Pd) catalysts have played a prominent role in the growing subfield of bioorthogonal catalysis by producing xenobiotics and uncaging biomolecules in living systems, and new exciting Pdcatalyzed reactions and applications continue to emerge. However, delivering catalysts selectively to specific cell types still lags behind catalyst development. Towards this goal, we have developed a bio-artificial device consisting of cancer-derived exosomes loaded with Pd catalysts by a novelmethod that enables the controlled assembly of Pd nanosheets directly inside the vesicles. This new hybrid system mediates Pdtriggered dealkylation reactions in vitro and inside cells and displays preferential tropism for their progenitor cells. The use of Trojan exosomes to deliver abiotic catalysts into designated cancer cells creates the opportunity for a new targeted therapy modality: exosome-directed catalyst prodrug therapy, whose first steps are presented herein with the cell-specific release of the recently approved anticancer drug panobinostat.
Idioma: Inglés
Año: 2019
Publicado en: HUMAN GENE THERAPY 30, 11 (2019), A63-A64
ISSN: 1043-0342
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.273 (2019)
Categ. JCR: BIOTECHNOLOGY & APPLIED MICROBIOLOGY rank: 30 / 156 = 0.192 (2019) - Q1 - T1
Categ. JCR: GENETICS & HEREDITY rank: 38 / 177 = 0.215 (2019) - Q1 - T1
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 40 / 138 = 0.29 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.648 - Genetics (Q1) - Molecular Medicine (Q1) - Molecular Biology (Q2)
Tipo y forma: Comunicación congreso (Versión definitiva)
Área (Departamento): Área Ingeniería Química (Dpto. Ing.Quím.Tecnol.Med.Amb.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2021-01-26-15:09:08)
Visitas y descargas
The transformational impact of bioorthogonal chemistries has inspired new strategies for the in vivo synthesis of bioactive agents through non-natural means. Among these, Palladium (Pd) catalysts have played a prominent role in the growing subfield of bioorthogonal catalysis by producing xenobiotics and uncaging biomolecules in living systems, and new exciting Pdcatalyzed reactions and applications continue to emerge. However, delivering catalysts selectively to specific cell types still lags behind catalyst development. Towards this goal, we have developed a bio-artificial device consisting of cancer-derived exosomes loaded with Pd catalysts by a novelmethod that enables the controlled assembly of Pd nanosheets directly inside the vesicles. This new hybrid system mediates Pdtriggered dealkylation reactions in vitro and inside cells and displays preferential tropism for their progenitor cells. The use of Trojan exosomes to deliver abiotic catalysts into designated cancer cells creates the opportunity for a new targeted therapy modality: exosome-directed catalyst prodrug therapy, whose first steps are presented herein with the cell-specific release of the recently approved anticancer drug panobinostat.
Idioma: Inglés
Año: 2019
Publicado en: HUMAN GENE THERAPY 30, 11 (2019), A63-A64
ISSN: 1043-0342
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.273 (2019)
Categ. JCR: BIOTECHNOLOGY & APPLIED MICROBIOLOGY rank: 30 / 156 = 0.192 (2019) - Q1 - T1
Categ. JCR: GENETICS & HEREDITY rank: 38 / 177 = 0.215 (2019) - Q1 - T1
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 40 / 138 = 0.29 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.648 - Genetics (Q1) - Molecular Medicine (Q1) - Molecular Biology (Q2)
Tipo y forma: Comunicación congreso (Versión definitiva)
Área (Departamento): Área Ingeniería Química (Dpto. Ing.Quím.Tecnol.Med.Amb.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2021-01-26-15:09:08)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2021-01-26, última modificación el 2021-01-26